Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Feb 25:2018:9128128.
doi: 10.1155/2018/9128128. eCollection 2018.

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy

Nice Bedini  1 , Alessandro Cicchetti  2   3 , Federica Palorini  2 , Tiziana Magnani  2 , Valentina Zuco  4 , Marzia Pennati  4 , Elisa Campi  4 , Paola Allavena  5 , Samantha Pesce  5 , Sergio Villa  1 , Barbara Avuzzi  1 , Sara Morlino  1 , Maria Emanuela Visentin  1 , Nadia Zaffaroni  4 , Tiziana Rancati  2 , Riccardo Valdagni  1   2   6
Affiliations
Clinical Trial

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy

Nice Bedini et al. Dis Markers. .

Abstract

A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma levels of the selected inflammatory molecules for all measurement points: absolute values (a, c, e, g, i, and k) and absolute variations with respect to baseline (b, d, f, h, j, and l). 1 mos: 1 month; RT: radiotherapy. Units of measure are pg/ml for IL-1b, IL-6, CXCL8, CCL2, and TNF alpha; ng/ml: PTX3.
Figure 2
Figure 2
Calibration plot for the linear regression model predicting CCL2 levels at end of radiotherapy (observed CCL2 levels at radiotherapy end versus CCL2 values as predicted by the linear regression). Details are given in the text. Units of measure pg/ml. RT: radiotherapy.
See this image and copyright information in PMC

References

    1. Defraene G., Van den Bergh L., Al-Mamgani A., et al. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2012;82(3):1233–1242. doi: 10.1016/j.ijrobp.2011.03.056. - DOI - PubMed
    1. Valdagni R., Vavassori V., Rancati T., et al. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiotherapy and Oncology. 2012;103(2):252–255. doi: 10.1016/j.radonc.2012.03.012. - DOI - PubMed
    1. Rubin P., Johnston C. J., Williams J. P., McDonald S., Finkelstein J. N. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. International Journal of Radiation Oncology, Biology, Physics. 1995;33(1):99–109. doi: 10.1016/0360-3016(95)00095-G. - DOI - PubMed
    1. Okunieff P., Chen Y., Maguire D. J., Huser A. K. Molecular markers of radiation-related normal tissue toxicity. Cancer Metastasis Reviews. 2008;27(3):363–374. doi: 10.1007/s10555-008-9138-7. - DOI - PMC - PubMed
    1. Liang L., Hu D., Liu W., Williams J. P., Okunieff P., Ding I. Celecoxib reduces skin damage after radiation. American Journal of Clinical Oncology. 2003;26(Supplement 2):S114–S121. doi: 10.1097/01.COC.0000074149.95710.40. - DOI - PubMed

Publication types